Logo

Shire's Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults

Share this

Shire's Motegrity (prucalopride) Receives FDA Approval for Chronic Idiopathic Constipation (CIC) in Adults

Shots:

  • The approval is based on six trials assessing Motegrity vs PBO in 2-484 patients with Chronic Idiopathic Constipation (CIC) in adults
  • P-III study results: normalization of BM frequency (19-38% vs 10-20%); no increase in the risk of MACE events
  • Motegrity (prucalopride) is a qd serotonin-4 receptor agonist (5-HT4) with its expected launch in 2019 in the US

Ref: GlobeNewWire | Image: WSJ

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions